CELEX: 62016CA0586
Language: en
Date: 2021-03-25 00:00:00
Title: Case C-586/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — Sun Pharmaceutical Industries Ltd, formerly Ranbaxy Laboratories Ltd, Ranbaxy (UK) Ltd v European Commission (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressant medicines (citalopram) — Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine)

31.5.2021   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 206/2
            
         
      Judgment of the Court (Fourth Chamber) of 25 March 2021 — Sun Pharmaceutical Industries Ltd, formerly Ranbaxy Laboratories Ltd, Ranbaxy (UK) Ltd v European Commission
      (Case C-586/16 P) (1)
      
      (Appeal - Competition - Agreements, decisions and concerted practices - Pharmaceutical products - Market for antidepressant medicines (citalopram) - Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines - Article 101 TFEU - Potential competition - Restriction by object - Characterisation - Calculation of the amount of the fine)
      (2021/C 206/02)
      Language of the case: English
      
         Parties
      
      
         Appellants: Sun Pharmaceutical Industries Ltd, formerly Ranbaxy Laboratories Ltd, Ranbaxy (UK) Ltd (represented by: R. Vidal, Solicitor, and B. Kennelly QC, and by L. Penny, Solicitor)
      
         Other party to the proceedings: European Commission (represented by: F. Castilla Contreras, T. Vecchi, B. Mongin and C. Vollrath, acting as Agents, and by B. Rayment and D. Bailey, Barristers, and by G. Peretz QC, and S. Kingston, Senior Counsel)
      
         Intervener in support of the defendant: United Kingdom of Great Britain and Northern Ireland (represented: initially by D. Guðmundsdóttir, Z. Lavery and D. Robertson, acting as Agents, and by J. Holmes QC, and subsequently by D. Guðmundsdóttir, acting as Agent, and by J. Holmes QC)
      
         Operative part of the judgment
      
      The Court:
      
                  1.
               
               
                  Dismisses the appeal;
               
            
                  2.
               
               
                  Orders Sun Pharmaceutical Industries Ltd and Ranbaxy (UK) Ltd to bear their own costs and to pay those incurred by the European Commission;
               
            
                  3.
               
               
                  Orders the United Kingdom of Great Britain and Northern Ireland to bear its own costs.
               
            
         (1)  OJ C 30, 30.1.2017.